Back to Search Start Over

The AUStralian MEDiterranean Diet Heart Trial (AUSMED Heart Trial): A randomized clinical trial in secondary prevention of coronary heart disease in a multiethnic Australian population: Study protocol

Authors :
Laima Brazionis
William J. van Gaal
Catherine Itsiopoulos
Antigone Kouris-Blazos
Hassan Vally
Teagan Kucianski
Leonie Segal
Andrew Wilson
Miguel Ángel Martínez-González
Agus Salim
Hannah L Mayr
Michael Kingsley
Colleen J. Thomas
Jessica Radcliffe
Audrey C. Tierney
Kerin O'Dea
Itsiopoulos, C
Kucianski, T
Mayr, H
van Gaal, W
Martinez-Gonzalez, M
Vally, H
Kingsley, M
Kouris-Blazos, A
Radcliffe, J
Segal, L
Brazionis, L
Salim, A
Tierney, A
O'Dea, K
Wilson, A
Thomas, CJ
Source :
American heart journal. 203
Publication Year :
2017

Abstract

The Mediterranean diet was first characterized as a heart-protective diet in the 1960s. The significant cardio-protective effects of the Mediterranean diet in comparison to the standard care low-fat diet have been established in the primary prevention of cardiovascular disease (CVD), however, there is insufficient evidence in secondary prevention research to influence the current standard of care. Opportunity exists to assess the Mediterranean diet as a therapeutic target for secondary CVD prevention within Australia's ethno-culturally diverse communities.The AUSMED Heart Trial is a multi-site randomized controlled trial that will evaluate the efficacy of the Mediterranean diet for secondary prevention of cardiovascular disease in the Australian healthcare setting. This trial aims to evaluate the effect of a 6-month Mediterranean diet intervention (delivered by dietitians) versus a ‘standard-care’ low-fat diet in reducing the composite incidence of cardiovascular events at 12 months and at trial end in participants with documented evidence of a previous Acute Myocardial Infarct (AMI) at trial entry. The quality of the diet at baseline and follow-up will be assessed using comprehensive dietary questionnaires and diaries as well as relevant dietary biomarkers (such as urinary polyphenols, erythrocyte fatty acids).Cardiovascular risk markers, including novel measures of immune and inflammatory status, endothelial function, vascular compliance, platelet activity and body composition, will be collected to explore possible mechanisms for treatment effect. Cost-effectiveness will also be estimated to support policy translation.We plan to recruit 1032 participants (516 per arm) from cardiology clinics in major Australian hospitals in Melbourne, Adelaide and Brisbane. Refereed/Peer-reviewed

Details

ISSN :
10976744
Volume :
203
Database :
OpenAIRE
Journal :
American heart journal
Accession number :
edsair.doi.dedup.....b0787de859cb558e147877c533ef2e13